Research Triangle Park-based CeNeRx BioPharma has raised $13 million to conduct Phase II trials of its experimental antidepressant. Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the Series C round.
CeNeRx is preparing to start a Phase II trial TriRima, the company's lead drug for treatment-resistant depression. "These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression," says CeNeRx CEO Barry Brand. "We are pleased with the continuing confidence and support of our investors and look forward to advancing the CeNeRx pipeline."
- check out the release from CeNeRx